141 related articles for article (PubMed ID: 33641723)
1. Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment.
Yang X; Li Y; Duan Q; Zhang Q; He M
J Thorac Oncol; 2021 Mar; 16(3):e17-e19. PubMed ID: 33641723
[No Abstract] [Full Text] [Related]
2. A lung adenocarcinoma patient harboring MET c. 3028 + 2 T >A variant sensitive to crizotinib treatment.
Jiang R; Wei D; Tan Y; Duan Q
Invest New Drugs; 2022 Aug; 40(4):870-873. PubMed ID: 35551560
[TBL] [Abstract][Full Text] [Related]
3. Novel MET Exon 14 Skipping Treatment-Naïve Lung Adenocarcinoma Presented Primary Resistance to Crizotinib.
Jiang W; Yang N; Zhang Y
J Thorac Oncol; 2018 Jul; 13(7):e124-e126. PubMed ID: 29935852
[No Abstract] [Full Text] [Related]
4. Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.
Zeng L; Xia C; Zhang Y; Yang N
J Thorac Oncol; 2019 Apr; 14(4):e70-e72. PubMed ID: 30922580
[No Abstract] [Full Text] [Related]
5. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.
Rotow JK; Woodard GA; Urisman A; McCoach CE; Bivona TG; Elicker BM; Jablons DM; Blakely CM
Clin Lung Cancer; 2019 Mar; 20(2):e137-e141. PubMed ID: 30553716
[No Abstract] [Full Text] [Related]
6. Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation.
Wiesweg M; Herold T; Metzenmacher M; Eberhardt WE; Reis H; Darwiche K; Aigner C; Stuschke M; Herrmann K; Nensa F; Schildhaus HU; Schuler M
Lung Cancer; 2020 Jan; 139():165-168. PubMed ID: 31809977
[TBL] [Abstract][Full Text] [Related]
7. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
Qin RY; Liu LS; Zhang HY; Lu CH; Guo XY; Zhang LY; Yuan XB; Xue HH
Medicine (Baltimore); 2021 Jan; 100(4):e24300. PubMed ID: 33530219
[TBL] [Abstract][Full Text] [Related]
8. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
9. MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma.
Miao YL; Xu QQ
Lung Cancer; 2019 Apr; 130():84-86. PubMed ID: 30885356
[TBL] [Abstract][Full Text] [Related]
10. Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.
Zhang Y; Yin J; Peng F
Lung Cancer; 2017 Nov; 113():69-71. PubMed ID: 29110851
[No Abstract] [Full Text] [Related]
11. Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.
Kauffmann-Guerrero D; Kahnert K; Kumbrink J; Syunyaeva Z; Tufman A; Huber RM
Clin Lung Cancer; 2019 Jan; 20(1):59-62. PubMed ID: 30341016
[No Abstract] [Full Text] [Related]
12. A Novel Intergenic Region between CENPA and DPYSL5-ALK Exon 20 Fusion Variant Responding to Crizotinib Treatment in a Patient with Lung Adenocarcinoma.
Fei X; Zhu L; Zhou H; Qi C; Wang C
J Thorac Oncol; 2019 Sep; 14(9):e191-e193. PubMed ID: 31445731
[No Abstract] [Full Text] [Related]
13. A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.
Mahjoubi L; Gazzah A; Besse B; Lacroix L; Soria JC
Invest New Drugs; 2016 Jun; 34(3):397-8. PubMed ID: 26892698
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing.
Zhu YC; Wang WX; Xu CW; Zhang QX; Du KQ; Chen G; Lv TF; Song Y
Ann Oncol; 2018 Dec; 29(12):2392-2393. PubMed ID: 30339198
[No Abstract] [Full Text] [Related]
15. Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.
Jin W; Shan B; Liu H; Zhou S; Li W; Pan J; Lin L; Hu D; Pan Y
J Thorac Oncol; 2019 Jul; 14(7):e137-e139. PubMed ID: 31055074
[No Abstract] [Full Text] [Related]
16. Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.
Shea M; Huberman MS; Costa DB
J Thorac Oncol; 2016 Jul; 11(7):e81-2. PubMed ID: 26845194
[No Abstract] [Full Text] [Related]
17. A Case of HLA-DRB1-MET Rearranged Lung Adenocarcinoma With Rapid Response to Crizotinib.
Kunte S; Stevenson J
Clin Lung Cancer; 2021 May; 22(3):e298-e300. PubMed ID: 32654927
[No Abstract] [Full Text] [Related]
18. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
Wang SXY; Zhang BM; Wakelee HA; Koontz MZ; Pan M; Diehn M; Kunder CA; Neal JW
Anticancer Drugs; 2019 Jun; 30(5):537-541. PubMed ID: 30762593
[TBL] [Abstract][Full Text] [Related]
19. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
[TBL] [Abstract][Full Text] [Related]
20. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
